Phio Pharmaceuticals Corp. (NASDAQ:PHIO) Short Interest Update

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) saw a large growth in short interest in February. As of February 28th, there was short interest totalling 66,700 shares, a growth of 46.6% from the February 13th total of 45,500 shares. Approximately 1.6% of the shares of the stock are sold short. Based on an average daily trading volume, of 6,080,000 shares, the short-interest ratio is presently 0.0 days.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and set a $4.00 target price on shares of Phio Pharmaceuticals in a research note on Wednesday, February 19th.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Phio Pharmaceuticals stock. Virtu Financial LLC bought a new position in shares of Phio Pharmaceuticals Corp. (NASDAQ:PHIO) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 40,910 shares of the company’s stock, valued at approximately $74,000. Virtu Financial LLC owned 0.59% of Phio Pharmaceuticals as of its most recent SEC filing. Hedge funds and other institutional investors own 57.31% of the company’s stock.

Phio Pharmaceuticals Price Performance

Shares of PHIO traded down $0.04 during mid-day trading on Friday, hitting $1.29. The company’s stock had a trading volume of 144,238 shares, compared to its average volume of 7,689,282. Phio Pharmaceuticals has a fifty-two week low of $1.22 and a fifty-two week high of $9.99. The stock has a market capitalization of $8.89 million, a price-to-earnings ratio of -0.12 and a beta of 1.28. The firm has a 50-day moving average price of $1.98 and a 200 day moving average price of $2.52.

Phio Pharmaceuticals Company Profile

Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors.